Venbio Partners 13F annual report

Venbio Partners is an investment fund managing more than $232 billion ran by Antoinette Delhonte. There are currently 6 companies in Mrs. Delhonte’s portfolio. The largest investments include Pharvaris N V and ALX Oncology, together worth $139 billion.

$232 billion Assets Under Management (AUM)

As of 7th August 2024, Venbio Partners’s top holding is 4,289,304 shares of Pharvaris N V currently worth over $80.6 billion and making up 34.8% of the portfolio value. In addition, the fund holds 9,699,925 shares of ALX Oncology worth $58.5 billion, whose value fell 65.6% in the past six months. The third-largest holding is Alumis Inc worth $37.6 billion and the next is Harmony Biosciences Hldgs In worth $31.2 billion, with 1,035,396 shares owned.

Currently, Venbio Partners's portfolio is worth at least $232 billion. The total portfolio value may be much higher due to cash assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.

Careers at Venbio Partners

The Venbio Partners office and employees reside in San Francisco, California. According to the last 13-F report filed with the SEC, Antoinette Delhonte serves as the Chief Financial Officer at Venbio Partners.

Recent trades

In the most recent 13F filing, Venbio Partners revealed that it had opened a new position in Alumis Inc and bought 2,826,048 shares worth $37.6 billion.

On the other hand, Antoinette Delhonte disclosed a decreased stake in Elevation Oncology Inc by approximately 0.1%. This leaves the value of the investment at $6.57 billion and 2,434,255 shares.

One of the smallest hedge funds

The two most similar investment funds to Venbio Partners are Mezzasalma Advisors and Horan Securities. They manage $232 billion and $231 billion respectively.

Antoinette Delhonte investment strategy

Venbio Partners’s portfolio is diversified across 2 sectors. Currently, their heaviest sector is Health Care — making up 25.3% of the total portfolio value. The fund focuses on investments in the United States as 16.7% of the portfolio companies are based in the United States.

The majority of the companies in the fund’s portfolio are large-cap stocks. Stocks with a size of more than $10 billion in market cap make up approximately 0.1% of the total holdings value. On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio. The average market cap of the portfolio companies is close to $422 million.

The complete list of Venbio Partners trades based on 13F SEC filings

These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.

Security	Shares Owned	Value	Allocation
Pharvaris N V	No change 4,289,304	$80,638,915,000	34.83%
ALX Oncology Holdings Inc.	No change 9,699,925	$58,490,548,000	25.26%
Alumis Inc	Opened 2,826,048	$37,586,438,000	16.23%
Harmony Biosciences Hldgs In	No change 1,035,396	$31,237,897,000	13.49%
Acelyrin Inc	No change 3,852,470	$16,989,393,000	7.34%
Elevation Oncology Inc	9.71% 2,434,255	$6,572,489,000	2.84%
No transactions found
Showing first 500 out of 6 holdings